TG Therapeutics Shows New Preliminary Data

Pharmaceutical Investing

TG Therapeutics revealed preliminary results from an ongoing Phase 2 study of TG-1101 treating patients with relapsing forms of multiple sclerosis.

TG Therapeutics (NASDAQ:TGTX) will reveal new preliminary results from an ongoing Phase 2 study of TG-1101 treating patients with relapsing forms of multiple sclerosis.
As quoted in the press release:

The data is being presented today at the 69^th American Academy of Neurology (AAN) annual meeting, taking place in Boston, MA. The poster is available for viewing during poster session 6, from 8:30 AM – 5:30 PM ET.
The poster, entitled “Preliminary results of Phase 2 Multicenter Study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of Multiple Sclerosis (RMS) demonstrates rapid and robust B cell depletion“ (Abstract Number: 3113; Poster number 6.348), includes data from 24 patients with RMS treated with TG-1101. Three dosing cohorts of up to 8 patients each were evaluated to assess the safety and tolerability of TG-1101 at accelerated infusion times.

Click here to read the full press release.

Source: globenewswire.com

american academy of neurology annual meeting antibody multiple sclerosis neurology patients phase 2 study relapsing forms of multiple sclerosis therapeutics Pharmaceutical Investing